Valtimotautia sairastavista potilasta jopa neljäsosalla on suurentunut triglyseridipitoisuus
tehokkaasta lipidilääkityksestä huolimatta. Tutkimuksen perusteella tehokkaan statiinihoidon
aikana todettu plasman triglyseriditaso ≥ 4 mmol/l suurentaa valtimotaudin
riskiä 52 % verrattuna joukkoon, jolla triglyseripitoisuus on < 1 mmol/l «Lawler PR, Kotrri G, Koh M ym. Real-world risk of ...»13.
Keskeinen aterogeenisyyden mekanismi näillä triglyseridirikkailla lipiproteiineilla
on sama kuin LDL-partikkeleilla eli ne siirtyvät endoteelin läpi verisuonen intimaan,
retentoituvat hepariinisulfaatti-glykoproteiinien välityksellä ja aikaansaavat vaahtosolujen
muodostumisen kautta ateroomaplakin muodostumisen «Tabas I, Williams KJ, Borén J. Subendothelial lipo...»8.
Ainoastaan suuret kylomikronipartikkelit eivät kokonsa vuoksi läpäise verisuonen endoteelia
eivätkä siten ole aterogeenisiä.
Kirjallisuutta
Krauss RM. Atherogenicity of triglyceride-rich lipoproteins. Am J Cardiol 1998;81:13B-17B
«PMID: 9526808»PubMed
Sarwar N, Danesh J, Eiriksdottir G ym. Triglycerides and the risk of coronary heart
disease: 10,158 incident cases among 262,525 participants in 29 Western prospective
studies. Circulation 2007;115:450-8 «PMID: 17190864»PubMed
Hokanson JE, Austin MA. Plasma triglyceride level is a risk factor for cardiovascular
disease independent of high-density lipoprotein cholesterol level: a meta-analysis
of population-based prospective studies. J Cardiovasc Risk 1996;3:213-9 «PMID: 8836866»PubMed
Bansal S, Buring JE, Rifai N ym. Fasting compared with nonfasting triglycerides and
risk of cardiovascular events in women. JAMA 2007;298:309-16 «PMID: 17635891»PubMed
Nordestgaard BG, Benn M, Schnohr P ym. Nonfasting triglycerides and risk of myocardial
infarction, ischemic heart disease, and death in men and women. JAMA 2007;298:299-308
«PMID: 17635890»PubMed
Jørgensen AB, Frikke-Schmidt R, West AS ym. Genetically elevated non-fasting triglycerides
and calculated remnant cholesterol as causal risk factors for myocardial infarction.
Eur Heart J 2013;34:1826-33 «PMID: 23248205»PubMed
Do R, Willer CJ, Schmidt EM ym. Common variants associated with plasma triglycerides
and risk for coronary artery disease. Nat Genet 2013;45:1345-52 «PMID: 24097064»PubMed
Tabas I, Williams KJ, Borén J. Subendothelial lipoprotein retention as the initiating
process in atherosclerosis: update and therapeutic implications. Circulation 2007;116:1832-44
«PMID: 17938300»PubMed
Catapano AL, Graham I, De Backer G ym. 2016 ESC/EAS Guidelines for the Management
of Dyslipidaemias. Eur Heart J 2016;37:2999-3058 «PMID: 27567407»PubMed
Emerging Risk Factors Collaboration., Di Angelantonio E, Gao P ym. Lipid-related markers
and cardiovascular disease prediction. JAMA 2012;307:2499-506 «PMID: 22797450»PubMed
Boekholdt SM, Arsenault BJ, Mora S ym. Association of LDL cholesterol, non-HDL cholesterol,
and apolipoprotein B levels with risk of cardiovascular events among patients treated
with statins: a meta-analysis. JAMA 2012;307:1302-9 «PMID: 22453571»PubMed
Robinson JG, Wang S, Jacobson TA. Meta-analysis of comparison of effectiveness of
lowering apolipoprotein B versus low-density lipoprotein cholesterol and nonhigh-density
lipoprotein cholesterol for cardiovascular risk reduction in randomized trials. Am
J Cardiol 2012;110:1468-76 «PMID: 22906895»PubMed
Lawler PR, Kotrri G, Koh M ym. Real-world risk of cardiovascular outcomes associated
with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease
and potential eligibility for emerging therapies. Eur Heart J 2020;41:86-94 «PMID: 31733058»PubMed